← Leaderboards
Xinning Wang
Case Western Reserve University
$1,410,982
Attributed
$3,650,635
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,650,635 · 2
By mechanism
R01$3,650,635 · 2
Top collaborators
- James Peter Basilion6 shared
- David Holt4 shared
Most similar at Case Western Reserve University
Same institution · by research overlap
- Nancy L Oleinick$4,281,905
- James Peter Basilion$13,402,848
- Peter A. Zimmerman$15,255,586
- Duska M Separovic$2,115,239
- Scot C Remick$11,938,221
Others in their field
Other Emerging Leaders on “Folh1 Gene”
- Nagavarakishore Pillarsetty · Sloan-Kettering Inst Can Research$3,488,347
- Robert A Bok · University Of California, San Francisco$3,250,145
- Daniel Lyndon Jaffe Thorek · Johns Hopkins University$2,921,109
- Rahul Aggarwal · University Of California, San Francisco$2,661,215
- Thomas Hope · University Of California, San Francisco$2,198,439
- Hunter Nicole Bomba · Cancer Targeted Technology, Llc$2,000,000
Research focus
Folh1 GeneLightClinical TranslationEfficacy TrialImmune ResponseLigandsCanis FamiliarisClinical ApplicationDoseDrug DevelopmentHigh RiskAntigen TargetingImmunocompetentIrradiationBiochemicalAnimalsBiological MarkersCessation Of LifeClinical TrialsDiagnosisCancer CellCancer EtiologyFutureMalignant Neoplasm Of Prostate
Grant awards (6)
Fluorescence image guided surgery, adjuvant PDT, and the immune response$577,657
R01 · FY2025 · EB
Highly selective targeted theranostics for prostate cancers$634,753
R01 · FY2024 · CA
Fluorescence image guided surgery, adjuvant PDT, and the immune response$586,967
R01 · FY2024 · EB
Highly selective targeted theranostics for prostate cancers$641,402
R01 · FY2023 · CA
Highly selective targeted theranostics for prostate cancers$645,854
R01 · FY2022 · CA
Highly selective targeted theranostics for prostate cancers$564,002
R01 · FY2021 · CA